Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Invion ( (AU:IVX) ).
Invion Limited has made significant progress in its clinical programs for Photosoft technology, including advancing its Phase I/II skin cancer trial by opening a second clinical site and completing dosing of five patients. The company has also expanded its collaboration with Hanlim Pharm to include oesophageal cancer, a market projected to grow significantly. Additionally, Invion secured $2 million through a share placement to accelerate its clinical programs, with the first tranche of funds already received. The company’s Photosoft technology was featured at Stanford Medicine’s Lung Cancer Summit, highlighting its innovative approach in cancer treatment.
More about Invion
Invion Limited is a company operating in the biotechnology industry, focusing on the development and commercialization of Photosoft technology for cancer treatment. The company is engaged in clinical programs targeting skin cancer and has expanded its focus to include oesophageal cancer through a collaboration with Hanlim Pharm.
YTD Price Performance: -28.00%
Average Trading Volume: 1,000
Technical Sentiment Signal: Buy
Current Market Cap: $5.48M
For a thorough assessment of IVX stock, go to TipRanks’ Stock Analysis page.